The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...
The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...
Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...
Liontown Resources Ltd (ASX: LTR) and Mesoblast Ltd (ASX: MSB) are two of four ASX shares falling on Friday. Here's ...
S&P/ASX All Ords Index (ASX: XAO) shares closed higher on the first day of trading for 2025, with these stocks clocking new ...
New data shows the 40 key ASX biotechs gained an average 50% in 2024 - but not all of them joined the winner's circle.
Top 2024 performers include multiple health care stocks with unique catalysts, as well as several quantum computing ...
A seismic shift in pediatric medical care has arrived with the FDA’s approval of Ryoncil (remestemcel-L-rknd), a ...
NEW YORK, Dec. 30, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem ...
Ending the year on a high note, the FDA's approval of Ryoncil, the first mesenchymal stromal cell (MSC)-based therapy, has been a pivotal moment for the regenerative medicine field. This milestone ...
The FDA's approval of Ryoncil, a mesenchymal stromal cell (MSC)-based therapy, has provided optimism in the cell therapy community, which BrainStorm sees as a positive sign for its MSC-based ...